Brawn Biotech Limited (BOM:530207)
India · Delayed Price · Currency is INR 18.60
-0.45 (-2.36%)
At close: Feb 11, 2026
Brawn Biotech Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Operating Revenue | 167.93 | 134.65 | 164.95 | 222.31 | 86.21 | 349.76 |
Other Revenue | 0.1 | 0.1 | - | 0.06 | 0 | - |
| 168.03 | 134.75 | 164.95 | 222.36 | 86.21 | 349.76 | |
Revenue Growth (YoY) | 23.10% | -18.30% | -25.82% | 157.93% | -75.35% | -29.51% |
Cost of Revenue | 146.92 | 120.92 | 145.22 | 193.25 | 68.88 | 300.27 |
Gross Profit | 21.11 | 13.83 | 19.73 | 29.11 | 17.33 | 49.49 |
Selling, General & Admin | 8.03 | 11.44 | 17.04 | 15.94 | 21.91 | 26.06 |
Other Operating Expenses | 20.62 | 20.01 | 17.33 | 16.14 | 15.45 | 29.1 |
Operating Expenses | 29.88 | 32.59 | 35.36 | 33.17 | 37.9 | 55.5 |
Operating Income | -8.77 | -18.76 | -15.63 | -4.05 | -20.57 | -6.01 |
Interest Expense | -0.04 | -0.03 | -0.57 | -0.07 | -0.11 | -0.19 |
Interest & Investment Income | 0.82 | 0.82 | 0.88 | 0.03 | - | 0.04 |
Currency Exchange Gain (Loss) | -0.01 | -0.01 | -0.05 | - | 0.02 | 2.74 |
Other Non Operating Income (Expenses) | 1.8 | -0 | -0.01 | -0.02 | -0.52 | -0.18 |
EBT Excluding Unusual Items | -6.2 | -17.99 | -15.38 | -4.12 | -21.18 | -3.6 |
Gain (Loss) on Sale of Assets | 0.01 | 0.01 | -0.06 | - | - | - |
Pretax Income | -6.19 | -17.98 | -15.44 | -4.12 | -21.18 | -3.6 |
Income Tax Expense | -0.58 | -0.58 | -2.97 | 4.57 | -4.73 | 1.91 |
Net Income | -5.61 | -17.4 | -12.47 | -8.68 | -16.44 | -5.51 |
Net Income to Common | -5.61 | -17.4 | -12.47 | -8.68 | -16.44 | -5.51 |
Shares Outstanding (Basic) | 3 | 3 | 3 | 3 | 3 | 3 |
Shares Outstanding (Diluted) | 3 | 3 | 3 | 3 | 3 | 3 |
EPS (Basic) | -2.02 | -5.80 | -4.16 | -2.89 | -5.48 | -1.84 |
EPS (Diluted) | -2.02 | -5.80 | -4.16 | -2.89 | -5.48 | -1.84 |
Free Cash Flow | -1.17 | -1.94 | -0.38 | 2.22 | -1.09 | 0.33 |
Free Cash Flow Per Share | -0.42 | -0.65 | -0.13 | 0.74 | -0.36 | 0.11 |
Gross Margin | 12.56% | 10.27% | 11.96% | 13.09% | 20.10% | 14.15% |
Operating Margin | -5.22% | -13.92% | -9.48% | -1.82% | -23.86% | -1.72% |
Profit Margin | -3.34% | -12.91% | -7.56% | -3.90% | -19.07% | -1.57% |
Free Cash Flow Margin | -0.70% | -1.44% | -0.23% | 1.00% | -1.27% | 0.10% |
EBITDA | -7.53 | -17.61 | -15.12 | -2.96 | -20.04 | -5.67 |
EBITDA Margin | -4.48% | -13.07% | -9.17% | -1.33% | -23.24% | -1.62% |
D&A For EBITDA | 1.24 | 1.15 | 0.51 | 1.09 | 0.53 | 0.34 |
EBIT | -8.77 | -18.76 | -15.63 | -4.05 | -20.57 | -6.01 |
EBIT Margin | -5.22% | -13.92% | -9.48% | -1.82% | -23.86% | -1.72% |
Revenue as Reported | 170.67 | 135.58 | 165.83 | 222.4 | 86.24 | 352.85 |
Advertising Expenses | - | 0.17 | 0.27 | 0.29 | 0.71 | 0.49 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.